NCT02344472View on ClinicalTrials.gov

Detect V / CHEVENDO (Chemo vs. Endo)

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

271

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

January 31, 2025

Study Completion Date

January 31, 2025

Conditions
Metastatic Breast Cancer
Interventions
DRUG

pertuzumab

HER2 targeted Therapy

DRUG

Trastuzumab

HER2 targeted Therapy

DRUG

Capecitabine

Chemotherapy

DRUG

Paclitaxel

Chemotherapy

DRUG

Vinorelbine

Chemotherapy

DRUG

Docetaxel

Chemotherapy

DRUG

Exemestane

endocrine therapy

DRUG

Letrozole

endocrine therapy

DRUG

Anastrozole

endocrine therapy

DRUG

Fulvestrant

endocrine therapy

DRUG

Ribociclib

CDK 4/6 inhibitor

DRUG

nab-Paclitaxel

chemotherapy

DRUG

eribulin

chemotherapy

DRUG

leuprorelin

endocrine therapy

DRUG

goserelin

endocrine therapy

Trial Locations (1)

Unknown

University Hospital Ulm Gynecology/Obstetrics, Ulm

Sponsors
All Listed Sponsors
collaborator

Roche Pharma AG

INDUSTRY

collaborator

Novartis Pharmaceuticals

INDUSTRY

collaborator

Eisai GmbH

INDUSTRY

collaborator

Celgene Corporation

INDUSTRY

lead

Prof. Wolfgang Janni

OTHER